Insulet Corp. PODD announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s ABT FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the United States. The latest development represents a significant step forward in the company’s efforts to expand access to its innovative, tubeless Omnipod 5 AID System for more people.
In August 2024, the FDA cleared Omnipod 5 for use by people with type 2 diabetes (18 years and above), expanding the technology to nearly six million insulin-requiring people in the United States.
PODD Stock’s Likely Trend Following the News
Following the announcement on Nov. 20, PODD shares climbed 1.8% on Wednesday, finishing at $266.58. The company’s solid innovation efforts and ongoing expansion of the Omnipod 5 platform are solidifying its market leadership. We expect the market sentiment toward PODD stock to remain positive surrounding this development.
Insulet has a market capitalization of $18.70 billion at present. Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 17.1% in 2024 on a 21.2% improvement in revenues. In the trailing four quarters, it delivered an earnings beat of 52.4%, on average.
Growing Presence of Insulet’s Omnipod 5
Insulet’s Omnipod 5 System simplifies diabetes management and has shown an improvement in results by removing the need for multiple daily injections (MDI) therapy and automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust technology. As the most prescribed and preferred pump in the United States, the waterproof, discreet and wearable Omnipod 5 is the first tubeless AID system that communicates with a CGM, proactively correcting for highs and helping protect against lows, day and night. The company states that the latest development will enable millions of Americans who take insulin to use Pod therapy with their preferred CGM sensor.
Image Source: Zacks Investment Research
The full U.S. market release of Omnipod 5 with Dexcom’s G7 CGM took place in June this year. Expanding global access to Omnipod 5 has been one of the top priorities for Insulet. Following a successful limited market release, Insulet made a full commercial launch of Omnipod 5 with Dexcom G6 and Abbott’s FreeStyle Libre 2 Plus in the United Kingdom and the Netherlands for individuals aged two years and older with type 1 diabetes. In France, Omnipod 5 is compatible with the G6 CGM and has received reimbursement status from the French National Authority for Health.
Industry Prospects Favoring Insulet
Per a Research report, the global diabetes devices market was valued at $30.31 billion in 2023 and is expected to witness a compound annual rate of 7.5% through 2030. The market is mainly being driven by the growing prevalence of diabetes, the rising usage of insulin-delivery devices and high obesity rates. The market is characterized by a high degree of innovation, focusing on creating solutions for more accurate and efficient diagnosis and treatment.
Other Developments in Insulet
Last month, Insulet announced the full market release of the Omnipod 5 App for iPhone in the United States. The app offers unique capabilities, such as a Custom Foods feature that allows users to input, save and list carbohydrate counts for their typical meal sizes, favorite foods and snacks. Users can select from their personalized list of foods when using the SmartBolus Calculator to determine how much insulin to receive for a meal, minimizing carb counting and simplifying mealtime math.
PODD Stock Price Performance
In the past year, Insulet shares have risen 40.6% compared with the industry’s growth of 19.8%.
PODD’s Zacks Rank and Key Picks
Insulet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Penumbra PEN and Globus Medical GMED, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra’s shares have risen 16.4% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Globus Medical’s 2024 earnings per share have increased 0.4% to $2.95 in the past 30 days. Shares of the company have surged 14% in the past year against the industry’s 4.1% fall. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpAbbott Laboratories (ABT) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
